CNS Pharmaceuticals, Inc.
CNSP
$6.66
$0.152.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.37% | 3.22% | 10.59% | 21.18% | 8.36% |
| Total Depreciation and Amortization | 14.71% | 14.29% | 0.00% | -19.05% | -39.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -84.87% | 25.12% | 40.68% | 42.38% | 44.27% |
| Change in Net Operating Assets | -353.96% | -249.05% | -170.60% | -199.86% | -59.47% |
| Cash from Operations | -14.47% | -93.92% | -37.22% | -21.03% | -1.94% |
| Capital Expenditure | -90.91% | -7.69% | -7.69% | -7.69% | -29.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -90.91% | -7.69% | -7.69% | -7.69% | -29.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 12.46% | 19.77% | 26.01% | 31.43% | 23.90% |
| Issuance of Common Stock | -10.99% | 261.59% | 227.32% | 343.23% | 152.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 435.19% | 478.70% | 501.77% | 67.08% | -- |
| Cash from Financing | -5.53% | 295.14% | 257.83% | 396.63% | 159.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -52.32% | 481.62% | 384.79% | 162.20% | 199.11% |